H
HALO
Halozyme Thrp
76.20
-2.42-3.08%After Hours: 76.07 -0.13 -0.17%19:43 07/10 EDT
OPEN/PREV CLOSE78.82/78.62
TODAY RANGE75.33-79.19
VOL1.47M
MARKET CAP9.04B
52 WEEK RANGE53.65-82.26
AVG VOL (3M)1.78M
% TURNOVER1.24%
TURNOVER--
P/E (TTM)27.41
% RANGE4.91%
EPS(TTM)2.780
P/E(FORWARD)11.26
P/B41.12
BVPS1.853
DIVIDEND--
P/S6.43
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP8.91B
SHARES OUTSTANDING118.61M
NEXT EARNINGS08/03-08/07
FREE FLOAT116.97M
LOT SIZE1
EX-DATE12/10/2003
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
How Halozyme’s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story
Simply Wall St·07/03 20:37
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued
Dow Jones·07/02 22:57
Stocks to Watch: Seer, Orthofix Medical, Halozyme Therapeutics
TipRanks·07/02 20:31
Halozyme announces key executive leadership transition and reorganization
Dow Jones·07/02 20:24
Halozyme Therapeutics Operating Chief Caudill to Exit
Simply Wall St·07/01 20:40
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative?
Reuters·06/30 20:02
BRIEF-Halozyme Appoints David Ramsay As President Drug Delivery
PUBT·06/30 20:02
Halozyme names David Ramsay president of drug delivery unit
Dow Jones·06/30 20:02
Press Release: Halozyme Appoints David Ramsay as President Drug Delivery
NASDAQ·06/25 10:18
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
TipRanks·06/22 13:43
LifeMD partners with Halozyme subsidiary for exclusive testosterone program